Baseline circulating immune cells from patients with no pCR have augmented cytotoxic response after treatment with pembrolizumab
Examining PD-1 expression on CD56+, CD8+, and CD14+ subsets reveals that PD-1 expression was present but there was no difference between pre- and post-treatment when divided based on treatment response (Supplementary Fig. 